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Abstract
Background: Malaria still represents a significant public health problem in China, and the cases dramatically
increased in Central China after 2001. Antifolate resistance in Plasmodium vivax is caused by point mutations in
genes encoding dihydrofolate reductase (pvdhfr) and dihydropteroate synthase (pvdhps). In this study, we used
direct sequencing to investigate genetic variation in pvdhfr of malaria patients’ samples from Central China.
Results: Among all the samples, 21.4% were wild-type, whereas mutations were detected at three codons (58, 61
and 117) including single mutant (34.6%) and double mutants (43.8%). The most prevalent mutant allele was the
one with double mutation at codons 58 and 117 (24.6%). Three types of single mutation (S58R, T61M and S117N)
were found in 2.1%, 11.8% and 20.9% of parasite isolates, respectively. The four P. vivax parasite populations in
Central China also differed in pvdhfr allele frequencies.
Conclusions: This study suggested that P. vivax in Central China may be relatively susceptible to pyrimethamine.
And it also highlights genotyping in the pvdhfr genes remains a useful tool to monitor the emergence and spread
of P. vivax pyrimethamine resistance.
Background
Plasmodium vivax is the major cause of malaria out-
side Africa, mainly in Asia and Americas [1]. Although
responsible for less mortality than P. falciparum, P.
vivax causes considerable morbidity, particularly in
children [2]. In China a total of 14491 malaria cases
and 59741 suspected cases with 12 deaths were
reported by the annual case reporting system in 2009
and more than 90% of the total cases were vivax
malaria cases [3]. In Central China, the re-emergence
of malaria was considerable in provinces along the
Huang-Huai River, especially in Anhui and Henan Pro-
vinces. The malaria prevalence increased considerably
with the highest incidence and over half of the total
malaria cases in 2006 in Anhui Province [4].
Since it is difficult to monitor the susceptibility of P.
vivax to antimalarial drugs by in vitro tests [5], molecu-
lar markers of drug resistance are useful tools for map-
ping the current and changing pattern of pyrimethamine
resistance of P. vivax isolates. Antifolate resistance is
strongly associated with mutations at specific sites in
t h eg e n ee n c o d i n gdhfr in malaria parasites [6]. In pro-
tozoans, dhfr and thymidylate synthases are parts of a
bifunctional enzyme encoded by a single gene. Some
research showed that by in vitro assays and kinetic stu-
dies of recombinant DHFR enzymes there are several
codons that may undergo amino acid substitutions [7-9].
To date, a number of non-synonymous mutations
including codons 33, 57, 58, 61, 117 and 173 in the
DHFR domain of P. vivax, have been reported world-
wide [10-17]. These mutant dhfr encode amino acid
sequences which are similar to those that cause antifo-
late resistance in P. falciparum, which suggests that
antifolate resistance in P. vivax could have arisen in the
same manner as that found in P. falciparum. It was also
very likely that antifolate-resistant P. vivax was selected
as a result of heavy deployment of antifolates against
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While this work was in progress, the kinetic properties
of both wild-type and mutant (S58R+S117N) recombi-
nant pvdhfr were reported [9]. Mutations in pvdhfr of
codons 58 and 117 are considered to be equivalent to
pfdhfr mutations at residues 59 and 108, respectively,
which are associated with pyrimethamine.
In China, an action plan for malaria elimination was
proposed by the Ministry of Health last year. The predo-
minant malaria parasite P. vivax in Central China has
demonstrated resilience to elimination and become
increasingly prevalent in Central China for the past 10
years [18]. With vivax malaria outbreaks occurring fre-
quently in many counties of central provinces in recent
years, vivax malaria has become predominant parasite
species and is responsible for more than 90% of malaria
cases in China. According to the antimalarial drug policy
of China, the first-line therapies for vivax malaria treat-
ment are chloroquine and primaquine, which have been
used for more than 60 years, and there is increasing evi-
dence showing the emergence and spread of chloroquine
resistance in vivax, especially in Southeast Asia [19].
Most of the studies on antifolate resistance in vivax
were performed in regions where vivax and falciparum
coexist. Because vivax malaria has not been directly
treated with antifolate drugs, the evolution of mutation
in the pvdhfr gene could only be inferred from possible
selection by treatment of falciparum malaria with antifo-
late drugs. Until now, mutations in pvdhfr has been stu-
died from limited vivax samples from temperate zone
countries, where vivax is the predominant malaria para-
site species and has a dramatically different relapse phe-
notype compared with tropical strains [20]. In the
present study, P. vivax isolates were collected from four
different sites in Central China, and the sequence of the
entire dhfr domain was determined to investigate
genetic variation in P. vivax dihydrofolate reductase.
Methods
Study area
In recent years the re-emergence of malaria was consid-
erable in Central China, especially along the Huang-
Huai River. Four counties in three provinces located in
Central China were selected for collecting blood samples
(Figure 1). The counties were Huaiyuan and Mengcheng
county in Anhui Province, Yongcheng county in Henan
Province, Guangshui city in Hubei Province. All the
counties were located at 32°17’~34°18’ north latitude,
113°~117°09’ east longitude with malaria re-emergence
in recent years.
Sample collection
A total of 187 blood samples from patients with acute P.
vivax infections with signs and symptoms associated
with malaria were collected from various clinics/hospi-
tals in different geographical locations in Central China.
The diagnosis was made by microscopic examination
of Giemsa-stained thin and thick blood smears, and
then a multiplex PCR was performed to confirm the
Plasmodium species. All the patients were found to be
infected only with P. vivax. An additional drop of blood
from finger pricked capillary blood was collected on 3M
Whatman filter papers for storage and transport of
infected blood samples after informed consent was
obtained. The filter papers were thoroughly dried, sealed
in a plastic bag with desiccant, and stored at -20°C.
All the blood samples were collected with the consent
of each patient and approval of the protocol was
obtained from the Institutional Research Ethical Com-
mittee prior to the study. Patients with a positive smear
were treated with chloroquine (total of 25 mg/kg body
weight in three divided daily doses) plus primaquine
(total of 180 mg in eight divided daily doses) according
to national guideline for treatment of P. vivax infections.
Parasite DNA extraction and amplification
The filter papers were thoroughly rinsed in 500 μlo f
sterile distilled water, placed in micro tube to which 50
μl of distilled water were added. DNA was extracted by
Chelex method [21].
A multiplex PCR using conditions described pre-
viously [22] was performed to confirm the Plasmodium
species in all isolates.
Figure 1 Map of distribution sentinel sites and mutant pvdhfr
in Central China.
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accession nos.98123), including 5-upstream non-coding
region, the following primer pairs were designed for the
nested PCR protocol: The primary amplification was
performed using the external primers, VDT-OF (5’-
ATGGAGGACCTTTCAGATGTATTTGACATT-3’)
and VDT-OR (5’-GGCGGCCATCTCCATGGTTATTT-
TAT CGTG-3’), wherein the entire P. vivax dhfr-ts gene
(1.8 kb) was amplified. This primary amplification pro-
duct was then used for performing nested PCR to
amplify pvdhfr domain (711 bp). The oligonucleotide
pair used was VDT-OF (5’-ATGGAGGACCTTTCA-
GATGTATTTGACATT-3’) and VDFNR (5’-TCA-
CACGGGTAGGCGCCGTTGATCCTCGTG-3’).
The reaction mixture consisted of template DNA (10
μl of genomic DNA extracted from filter papers for the
primary amplification and 1 μl of the primary reaction
for the secondary nested PCR), 15 pmol of forward and
reverse primers, buffer (50 mM KCl, 10 mM Tris, pH
8.3), 1.5 mM MgCl2,2 0 0μM deoxynucleoside tripho-
sphates, and 1 unit of Taq DNA polymerase (Promega,
USA) in a final volume of 50 μl. The PTC-100 thermal
cycler (PTC-200, Bio-Rad, USA) was programmed as
follows: 94°C for 2 min for the first cycle and 30 s in
subsequent cycles, 50°C for 1 min for the first cycle and
30 s in subsequent cycles, and 72°C for 1 min for all
cycles, for a total of 30 cycles, followed by a 15 min
extension step at 72°C. The amplified PCR products
were then analyzed on 2% agarose gel, stained with ethi-
dium bromide, and visualized under ultraviolet illumina-
tion. All the samples showed specific amplification in
the present study.
Sequence analysis
The amplified products were purified from agarose gel
and sequenced by automated DNA sequence (ABI sys-
tems, Perkin-Elmer, France). Sequence alignments and
analysis was carried out using Mega and Bioedit soft-
ware. Amino acid sequences were compared with wild-
type sequences (GenBank accession nos.98123 for
pvdhfr)
Results
Malaria situation
The malaria transmission in Central China was very low
in 1990’s, and malaria was basically eliminated in most
areas with malaria incidence less than 1/10,000. How-
ever, early in the 21
th century, malaria has reemerged in
these areas, especially the Anhui Province.
From Figure 2, malaria reemerged in Yongcheng,
Mengcheng and Huaiyuan Counties from 2000 and the
incidence of Yongcheng County was highest with
122.41/100,000 in 2007 while malaria is relatively stable
in Guangshui City. In these areas, there was a plain
landscape with soybean as the primary crop, and it was
a fixed vectorial area, including An. sinensis and An.
anthropophagus based on historical vectorial investiga-
tions in the Huang-Huai River region. The average vec-
tor capacity in this area was 0.1686 in 1990’s.
Zhou [23] found that the spatial distribution between
malaria cases and water-body, the changing of meteoro-
logical factors, and increasing vectorial capacity and
b a s i cr e p r o d u c t i v er a t eo fAn. sinensis lead to malaria
re-emergence in these areas.
Mutations in the pvdhfr gene
Total of 187 samples were collected and all the samples
were confirmed to be P. vivax by PCR (data not shown).
Pvdhfr gene sequences from a total of 187 P. vivax sam-
ples were amplified by primary and nested PCR.
Sequence polymorphism was assessed in pvdhfr genes
from 187 P. vivax samples. Compared with the wild-type
sequence (GenBank accession nos.98123), pvdhfr genes
from the 187 samples had point mutations, among which
three resulted in amino acid substitutions. No synon-
ymous mutations were detected at positions 58, 61 and
1 1 7 ,a n dt h ep o i n tm u t a t i o na tc o d o n s5 7a n d1 7 3w a s
not observed in the samples. The S117T mutation was
the most prevalent (20.9%), followed by the T61M muta-
tion. Among all the samples, 21.4% were wild-type,
whereas mutations were detected at three codons (58, 61
and 117) including single mutant (34.8%) and double
mutants (43.8%) without triple mutations. The propor-
tions of wild type and mutant pvdhfr alleles were differ-
ent in different provinces (showed in Figure 3).
On the basis of amino acid changes, the pvdhfr
sequences can be grouped into six alleles. Except for the
wild-type allele, the most prevalent mutant allele was
the one with double mutation at codons 58 and 117
(24.6%). Three types of single mutation (S58R, T61M
and S117N) were found in 2.1%, 11.8% and 20.9% of
parasite isolates, respectively. The four P. vivax parasite
populations in Central China also differed in pvdhfr
allele frequencies (Table 1). 147 of 187 samples yielded
Figure 2 Malaria incidences in Huaiyuan, Mengcheng,
Yongcheng and Guangshui Counties from year 1990 to 2009
from case report system.
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isolates carried the key double mutations associated with
pyrimethamine resistance, S58R and S117N, which cor-
respond to Cys59Arg and Ser108Asn substitutions in P.
falciparum, respectively.
These changes and corresponding positions of muta-
tions observed in pvdhfr were shown in Table 1. Various
numbers of wild-type alleles were identified from para-
sites originating from different regions with frequencies
ranging from 12.7% to 44.4%.
Discussion
In terms of morbidity, P. vivax infections account for a
considerable part of malarial disease and economic bur-
den in China and elsewhere in Southeast Asia, calling
for increasing research effort to understand the epide-
miology of P. vivax [2].
The current standard treatment of P. vivax for chloro-
quine-sensitive infections recommended by WHO is
chloroquine 25 mg base/kg bw divided over 3 days,
combined with primaquine 0.25 mg base/kg bw, taken
with food once daily for 14 days to eliminate hypno-
zoites[24]. In China, the first line drugs for the current
treatment of P. vivax are chloroquine plus primaquine
and the total dosage of primaquine (180 mg dosage for
8 days) is different from WHO recommendation. The
second line drugs was artemisinin combined therapy
(ACT), which includes four types [25].
Mutations in the pvdhfr gene are known to be asso-
ciated with resistance to antifolate drugs. Although anti-
folates were used to treat P. falciparum malaria, very
little information was available about the origin and
spread of this drug resistance in P. vivax. Allelic diver-
sity at flanking microsatellite loci of the dhfr gene will
be helpful in understanding the origin and spread of
antifolate resistance in P. vivax populations as well as
the evolutionary history of the parasite species. There-
fore, we planned to analyze the extent of these muta-
tions in P. vivax populations in Central China, by
isolating and sequencing the dhfr gene for 187 P. vivax
isolates originating from different geographical regions
of Central China. This is the first study to investigate
pvdhfr polymorphisms in Central China.
In the present study, we have analyzed pvdhfr gene
sequences from 187 P. vivax isolates from different geo-
graphical regions in Central China (Figure 1). Analysis
of pvdhfr sequences showed limited polymorphism as
compared to earlier studies. Approximately half of the
P. vivax isolates obtained in Central China present the
k e yd o u b l eA r g - 5 8 / A s n - 1 1 7m u t a t i o n si nt h edhfr gene
Figure 3 The Pie charts show the proportions of wild type and
mutant pvdhfr alleles.
Table 1 Prevalence of pvdhfr mutant alleles in P.vivax
isolates from Central China
Region Pvdfhr
N(%) 57 58 61 117 173
Wild type F S T S I
Huaiyuan County 17(27.0) F S T S I
0F R T S I
9(14.3) F S M S I
23(36.5) F S T N I
10(15.9) F R T N I
4(6.3) F S M N I
Mengcheng County 11(21.2) F S T S I
2(3.8) F R T S I
4(7.7) F S M S I
7(13.5) F S T N I
17(32.6) F R T N I
11(21.2) F S M N I
Yongcheng County 8(12.7) F S T S I
2(3.2) F R T S I
9(14.3) F S M S I
8(12.7) F S T N I
15(23.8) F R T N I
21(33.3) F S M N I
Guangshui City 4(44.4) F S T S I
0F R T S I
0F S M S I
1(11.2) F S T N I
4(44.4) F R TN I
0F S M N I
Total 187
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Cambodia [26], Myanmar [15], Thailand [27] and Viet-
n a m[ 2 8 ] .B u tw ed i dn o tf i n dt r i p l ea n dq u a d r u p l e
mutations just as that of recent study in China, Thai-
land, Vietnam and Korea [29,30]. Likewise, none of the
Cambodia, Thailand, and Myanmar isolates studied had
the mutant Leu-173, homologous to Ile164Leu substitu-
tion in the P. falciparum dhfr associated with a high
level antifolate resistance. However, in contrast to Thai-
land isolates, which showed a high proportion (54%) of
mutant Leu-57, all isolates in our studies had the wild
type Phe-57 codon.
Pyrimethamine was used for radical treatment of P.
vivax combined with primaquine 40 years ago [unpub-
lished data]. Also, pyrimethamine was added to salt for
prophylaxis in 1980’s. Pyrimethamine plus primaquine
were recommended as prophylaxis of medicine for spe-
cific populations in China in 1980’s [31]. Surprisingly, in
our study there is a difference in pvdhfr allele frequen-
cies between the sentinel sites, but the reason was not
clear. So far, no data is available on its susceptibility to
pyrimethamine. There were different population struc-
tures and genetic polymorphisms in P.vivax and it could
be postulated that they have a different susceptibility to
pyrimethamine. Besides, it has been hypothesized that
the S117N mutation represents the first step in the
drug-resistance selection process that has occurred in
the parasite [32].
For vivax malaria resistance in China, only one report
showed the data of in vitro susceptibility to chloroquine
of P. vivax isolate in Central China and the geometric
mean IC50 of chloroquine was 63.23 nmol/L and
although 6 isolates showed resistance to chloroquine in
vitro, we cannot conclude that there was chloroquine
resistance in China [33].
Limitation
Although our study showed that P. vivax in Central
China may be relatively susceptible to pyrimethamine, it
was not recommended in national antimalarial drug pol-
icy for the treatment or prophylaxis of vivax malaria
treatment. A previous study [33] has found vivax isolates
are resistant to chloroquine in vitro,t h e r e f o r es o m e
related to chloroquine-resistance gene will be tested in
the future.
Conclusions
However, from the molecular viewpoint, it is of interest
to analyze, as in the case of P. falciparum,t ow h a t
extent a molecular marker, or set of markers, can pre-
dict the parasitological and clinical outcome of antima-
larial drug treatment. Further molecular characterization
of P. vivax isolates from different endemic areas may be
a useful alternative approach to establish the epidemiol-
ogy of drug-resistant malaria.
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